Amitrole

Amitrole

SCHEMBL1872800

N.NS(=O)(=O)O.Nc1nc[nH]n1

nearest known ligand 0.35

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
TSHR P16473 1/20 0.33
NT5E P21589 1/20 0.33
CA4 P22748 1/20 0.33
CA6 P23280 1/20 0.33
CA5A P35218 1/20 0.33
CA7 P43166 1/20 0.33
CA9 Q16790 1/20 0.33
CA5B Q9Y2D0 1/20 0.33
KDM4E B2RXH2 1/20 0.31
CYP1A2 P05177 1/20 0.30
CYP2C19 P33261 1/20 0.30
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Amitrole SCHEMBL11745846 0.91 KDM4E (0.32) KDM4E
Cadaverine Tartrate SCHEMBL9751938 0.84 KDM4E (0.31) TSHRKDM4EHSD17B10
Amitrole SCHEMBL788110 0.82 HSP90AA1 (0.33)
Amitrole SCHEMBL44637 0.82
Amitrole SCHEMBL10550888 0.79
Amitrole SCHEMBL10399233 0.79
Amitrole SCHEMBL31379743 0.79
Amitrole SCHEMBL2892139 0.78
Amitrole SCHEMBL1172473 0.75 RXFP1 (0.45) CA5ACA5B
Amitrole SCHEMBL5613985 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10357030-B2 Methods for generating high aspect-ratio polymeric particles comprising an active ingredient SYNGENTA PARTICIPATIONS AG (CH) 2019-07-23 US disclosed
US-20180303085-A1 METHODS FOR GENERATING HIGH ASPECT-RATIO POLYMERIC PARTICLES COMPRISING AN ACTIVE INGREDIENT SYNGENTA PARTICIPATIONS AG (CH) 2018-10-25 US disclosed
US-10004223-B2 Methods for generating high aspect-ratio polymeric particles comprising an active ingredient SYNGENTA CROP PROTECTION LLC (US) 2018-06-26 US disclosed
US-20120329648-A1 METHODS FOR GENERATING HIGH ASPECT-RATIO POLYMERIC PARTICLES COMPRISING AN ACTIVE INGREDIENT SYNGENTA CROP PROTECTION LLC (US) 2012-12-27 US disclosed
EP-2498598-A1 METHODS FOR GENERATING HIGH ASPECT RATIO POLYMERIC PARTICLES COMPRISING AN ACTIVE INGREDIENT Syngenta Participations AG (CH) 2012-09-19 EP disclosed
WO-2011060210-A1 METHODS FOR GENERATING HIGH ASPECT RATIO POLYMERIC PARTICLES COMPRISING AN ACTIVE INGREDIENT SYNGENTA PARTICIPATIONS AG (CH) 2011-05-19 WO disclosed
WO-2008115934-A1 METHODS FOR GENERATING NON CELLULOSE MICROFIBRES COMPRISING AN ACTIVE INGREDIENT SYNGENTA PARTICIPATIONS AG (CH) 2008-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329648-A1 METHODS FOR GENERATING HIGH ASPECT-RATIO POLYMERIC PARTICLES COMPRISING AN ACTIVE INGREDIENT ALG1, AGPS, PFAS CA1 3441/4885CA2 4383/4885TSHR 4815/4885
US-20180303085-A1 METHODS FOR GENERATING HIGH ASPECT-RATIO POLYMERIC PARTICLES COMPRISING AN ACTIVE INGREDIENT LIPA, ALG1, PLIN3 CA1 2851/4885CA2 3909/4885TSHR 4859/4885
US-10004223-B2 Methods for generating high aspect-ratio polymeric particles comprising an active ingredient ALG1, AGPS, PFAS CA1 3441/4885CA2 4383/4885TSHR 4815/4885
US-10357030-B2 Methods for generating high aspect-ratio polymeric particles comprising an active ingredient LIPA, ALG1, PLIN3 CA1 2851/4885CA2 3909/4885TSHR 4859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.